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We report 2 families with undiagnosed recessive presynaptic congenital myasthenic syndrome (CMS). Whole exome or genome sequencing identified segregating homozygous variants in VAMP1: c.51_ 64delAGGTGGGGGTCCCC in a Kuwaiti family and c.146G>C in an Israeli family. VAMP1 is crucial for vesicle fusion at presynaptic neuromuscular junction (NMJ). Electrodiagnostic examination showed severely low compound muscle action potentials and presynaptic impairment. We assessed the effect of the nonsense mutation on mRNA levels and evaluated the NMJ transmission in VAMP1 lew/lew mice, observing neurophysiological features of presynaptic impairment, similar to the patients. Taken together, our findings highlight VAMP1 homozygous mutations as a cause of presynaptic CMS. ANN NEUROL 2017; 81:597-603 T he congenital myasthenic syndromes (CMSs) are a heterogeneous group of inherited diseases of the neuromuscular junction (NMJ), with fatigable muscle weakness as the clinical hallmark. 1 Several molecular causes can be implicated in CMS pathophysiology, including mutations in genes encoding proteins associated with the muscle nicotinic acetylcholine receptor and the synaptic basal lamina, or (more rarely) involved in the NMJ presynaptic transmission. [2] [3] [4] [5] [6] We describe 2 families from Kuwait and Israel where 2 of the siblings in each family presented clinical and neurophysiological features typical of a presynaptic CMS. Whole exome sequencing (WES) or whole genome sequencing (WGS) followed by Sanger sequencing unraveled either a homozygous frameshift or missense variants in VAMP1 segregating with the phenotype in the 2 families. Screening a cohort of 63 undiagnosed CMS individuals failed to show any further causative variant in VAMP1.
Materials and Methods

Subjects
This study was approved by the institutional review boards of the participating centers. Informed consent was obtained from the families. Clinical details were obtained from medical records. Neurophysiological studies were performed according to standard procedures. 7, 8 
Genetic Studies
Before WES, the Kuwaiti probands (Family 1) underwent extensive molecular investigations that included sequencing of AGRN, mitochondrial DNA (mtDNA) sequencing, and deletion/duplication analysis and array comparative genome hybridization, which were all negative. Clinical trio-based WES of Family 1 and WGS of the Israeli probands and their parents (Family 2) were performed as previously described. 9 
Results
Clinical and Neurophysiological Characteristics Fig 1A) presented shortly after birth with hypotonia and muscular weakness. Feeding difficulties requiring gavage feeding, delayed motor development, and ophthalmoparesis characterized the disease course. A.II-3 also presented joint contractures. Creatine kinase and plasma lactate were normal in the 2 children. On initial evaluation of Patient A.II-3, muscle biopsy showed myopathic features and borderline low complex IV activity (0.011; normal range 5 0.014-0.034), but congenital myopathy gene panel and mtDNA analysis were negative. Although hypotonia slightly improved in Patient A.II-1, at the age of 3 years she still had difficulties standing upright and was unable to walk without support. Electrodiagnostic examination (EDX) in the 2 individuals showed similar findings (Table) , with marked reduction in the amplitude of the compound muscle action potentials (CMAPs) and an increase in the amplitude to >200% of baseline on repetitive nerve stimulation (RNS) to 20Hz, indicating presynaptic impairment of NMJ transmission. The children's weakness slightly ameliorated under pyridostigmine treatment.
FAMILY 2. The affected individuals of this family (B.II-2 and B.II-3; see Fig 1B) showed severe hypotonia and muscle weakness since birth. Both siblings had feeding difficulties and required percutaneous endoscopic gastrostomy. They presented severe impairment of developmental milestones. B.II-1 also showed joint laxity and kyphoscoliosis. B.II-3 presented knee contractures and breathing difficulties. During disease course, both children showed markedly reduced ability to generate antigravity posture and movements. B.II-2 never reached autonomous walk; his EDX showed severely low CMAPs and increased neuromuscular jitter, indicating NMJ transmission abnormalities (see Table 1 ). In both siblings, pyridostigmine treatment improved symptoms.
Identification of the VAMP1 Mutation
Trio-based WES of Family 1 (A.I-1, A.I-2, A.II-1; see Fig 1A) indicated in the index case 3 genes (Supplementary Table 1 ) carrying homozygous exonic variants predicted to have a possible pathogenic effect on protein function, based on the guidelines for variant classification. 13 Full Sanger-based segregation analysis of the candidate variants reduced the gene list to only 1 mutation in VAMP1 (NM_014231: c.51_64delAGGTGGGG GTCCCC; p.Gly18TrpfsTer5*), which was found to be homozygous in the affected individuals and heterozygous in their healthy sister and in the unaffected parents (see Fig 1C; data shown for the index case and her parents). Table 2 ), which were homozygous in the affected individuals and heterozygous in the parents. 12 Among these 6 variants, a homozygous missense mutation in VAMP1 (NM_014231: c.146G>C; p.Arg49Pro; see Fig 1D) emerged as the most likely explanation for the disease pathogenesis, as supported by protein function (the mutation affects a conserved amino acid within the active domain of the protein), 14, 15 expression and role of this gene in the NMJ, 12, 16 and the homozygous mutation identified in the patients from Family 1 presenting the same phenotype (see Fig 1C-G) .
RT-PCR assay (performed to analyze possible nonsense-mediated decay associated with the VAMP1 truncating variant in Family 1) found a mild reduction of mutant cDNA expression in the index case compared to the heterozygous carriers and the wild-type control (see Fig 1E, F) . abnormalities similarly to affected individuals, we reexamined Vamp1 lew/lew mutant mice that were previously described. 11, 12 The endplates were localized along the central regions of the muscle in both control and Vamp1 lew/lew mice (Fig 2) . Individual neuromuscular synapses were found markedly smaller in Vamp1 lew/lew mice compared with control, and a severe reduction in endplate potentials (EPPs) was also observed in the mutant mice. Importantly, a low-frequency, repetitive stimulation (10Hz) led to a run-down of EPPs in control mice, but synaptic facilitation in Vamp1 lew/lew mice, indicating presynaptic defects.
Impairments of the Neuromuscular Junction in
Discussion
Here, we report 4 children from 2 consanguineous families who presented with typical clinical and neurophysiological features of presynaptic CMS associated with homozygous mutations in VAMP1.
The protein encoded by this gene is a member of the synaptobrevin family.
14 Synaptobrevins (eg, Vamp1, Vamp2), syntaxins, and the synaptosomalassociated protein Snap25 represent the main components of the SNARE (soluble N -ethylmaleimidesensitive factor attachment protein receptors) complex, which is involved in docking and fusion of synaptic vesicles with the presynaptic membrane at the central and the neuromuscular synapses. 15, 16 Proteins belonging to this complex are involved in vesicle docking through the evolutionarily conserved active v-SNARE coiled coil homology domain and present high sequence similarity across the different SNAREs. [17] [18] [19] Notably, the c.51_64delAGGTGGGGGTCCCC frameshift deletion identified in Family 1 leads to a change in the gene reading frame with the generation of a premature stop codon 5 amino acids downstream (see Fig 1H) . The result is a putative VAMP1 product of only 21 amino acids, with a resulting function that is highly likely to be disrupted due to the absence of the downstream v-SNARE domain (amino acids 33-93). The homozygous mutation identified in Family 2 consists of a substitution of a highly conserved arginine (Gerp11 score 5 5.77) by a proline within the v-SNARE domain. The mutated arginine residue in position 49 corresponds to the arginine in position 47 of the better-studied SNARE homolog VAMP2, encoding another synaptobrevin with similar functions to VAMP1.
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Interestingly, it has been shown that disruption of this specific site in VAMP2 interferes with SNARE complex assembly, impairing neurotransmission, likely due to lack of association with other proteins involved in vesicle fusion. [21] [22] [23] The Arg49Pro mutation is predicted as dele- biallelic VAMP1 variants, either resulting in changes of the gene reading frame or affecting conserved active sites crucial to v-SNARE domain function.
Interestingly, we also showed that the electrodiagnostic anomalies recorded in VAMP1-associated CMS are consistent with the abnormal features of presynaptic transmission we recorded in the VAMP1 null mutant mice (including the incremental response to RNS; see Fig 2) . These animals, of a model called lethal wasting (carrying a homozygous mutation that causes the truncation of half of the protein), lack movement because of an impaired NMJ transmission and die within 3 weeks of birth. 11, 12 To date, biallelic variants in VAMP1 have never been reported, but heterozygous mutations in this gene have been described by a single study in association with a phenotype of autosomal dominant spastic ataxia. 23 However, we have not observed any neurological phenotype in the heterozygous carriers from the 2 families.
In conclusion, the identification of biallelic variants in VAMP1 as a novel cause of CMS, in addition to other genes (eg, SNAP25B, SYT2) previously associated with similar presynaptic abnormalities of neuromuscular transmission, 5, 6 highlights the crucial role of different SNAREs in NMJ physiology. Intriguingly, the relatively mild phenotype showed by our patients compared to the mouse model, which dies prematurely, suggests the possible existence of species-specific compensation of vesicle fusion and release at the nerve terminal, perhaps through genetic modifiers in humans but not in mice or fruit flies. This highlights a promising area of future research aimed at the pathways involved in physiological presynaptic vesicle exocytosis at the motor endplate.
